CurrentBlue Cross Blue Shield - MassachusettsPolicy BCBSA 7.01.177

Processed nerve allografts and synthetic nerve conduits for peripheral nerve gap repair

Medical coverage policy for use of processed nerve allografts and synthetic nerve conduits to repair peripheral nerve gaps, governing Commercial and Medicare members of Blue Cross Blue Shield Massachusetts.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyProcessed nerve allografts and synthetic nerve conduits for peripheral nerve gap repair

Policy CodePolicy BCBSA 7.01.177

Change TypeNo material changes

Effective DateAug 1, 2025

Next Review Date

Key ActionObtain precertification/preauthorization for procedures performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤70 mmmaximum allograft length considered medically necessary

15-25 mmdigital nerve gap range (conduits if allograft unavailable)

≤6 mmmajor nerve small gap threshold (conduits if allograft unavailable)

inpatientprior authorization requirement (inpatient)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Processed nerve allograft — Initial coverage

Covered when ALL of the following are met for processed nerve allograft:

Allograft coverage: Use of processed nerve allografts for repair and closure of peripheral nerve gaps when direct primary repair is not feasible.gap <= 70 mm

Direct primary repair must be infeasible (see Policy Guidelines).

Synthetic nerve conduits — Permitted indications

Synthetic nerve conduits are considered medically necessary in the following specific scenarios:

Conduit scenarios: Conduit repair is medically necessary for: 1) repair of digital nerve injuries with gaps 15-25 mm when allograft nerve is not available; OR 2) repair of digital nerve injuries with gaps <15 mm; OR 3) repair of major nerves with small gaps not exceeding 6 mm when allograft nerve is not available; OR 4) conduit-assisted repair used as a tension-relief technique at the peripheral nerve repair site.gap criteria per scenario

Conduit repair for 15-25 mm digital nerve gaps should be used only when allograft is not immediately available (e.g., urgent trauma).

Investigational / Not medically necessary

Investigational/Not covered uses:

Investigational uses: All other uses of processed nerve allografts and synthetic nerve conduits for peripheral nerve gaps not listed as medically necessary are considered investigational.N/A

Evidence is insufficient to demonstrate an improvement in net health outcome for other indications due to study limitations and heterogeneity.

Both processed nerve allograft and synthetic nerve conduit repair are contraindicated when the procedure would occur in a surgical field with an active infection. This is an explicit exclusion and would be a basis for claim denial or noncoverage.

The referenced document sections here provide links to Blue Cross Blue Shield policy governance resources such as the Medical Policy Terms of Use, Managed Care Guidelines, Clinical Exception Process, and related guidance. These chunks do not state additional clinical exclusions or coverage rules; they point readers to policy administration materials and managed-care resources.

Uses of processed nerve allografts and synthetic nerve conduits beyond the specific medically necessary indications listed in this policy are considered investigational. The summary of evidence notes significant heterogeneity across studies and limitations in trial quality, and concludes that the evidence is insufficient to determine improvement in net health outcome for other indications.

The provided chunks do not contain explicit statements labeling additional specific services as not medically necessary. Instead, these sections link to general policy governance materials (for example, Medical Policy Terms of Use and Managed Care Guidelines) without specific denial language.

Coding

Covered CPT Codes (informational list)CPT

64910
64912	Nerve repair; with nerve allograft, each nerve, first strand (cable)
64913	Nerve repair; with nerve allograft, each additional strand (List separately in addition to...)

inv-09: Maximum allograft length — 70 mm

Maximum allograft length70 mm

ApplicabilityUsed to bridge peripheral nerve gaps when direct primary repair is not feasible

Implication for repair planningNo data to support connecting allografts end-to-end; plan repairs within single-graft length limits

Provider Actions & Authorization

Prior Authorization

Prior Authorization Required for Inpatient Procedures

Precertification/prior authorization is required for all procedures described in this policy when performed in the inpatient setting. For outpatient procedures, prior authorization requirements vary by product — some commercial and Medicare product lines may not require outpatient prior authorization. Providers should confirm product-specific outpatient authorization rules with the member's plan.

Inpatient procedures: prior authorization required for all products.
Outpatient procedures: prior authorization may be required depending on product; verify with the member's plan.

Note

Autograft Preferred When Feasible

Autograft (patient's own nerve tissue) is the preferred repair method when feasible and sufficient donor material is available, and is generally considered the standard intervention for larger sensory, motor, or mixed nerve repairs. Allograft or conduits may be considered when autograft is not feasible (e.g., insufficient donor tissue) or when avoiding donor-site morbidity is a priority.

Background

Peripheral nerve injuries commonly result from trauma and may require surgical intervention to permit axonal regeneration and functional recovery. When primary tensionless repair is not feasible because of segmental loss or gap length, grafting or conduit techniques are used to bridge the defect. Processed nerve allografts are human donor–derived, decellularized nerve scaffolds designed to bridge gaps (available in lengths up to 70 mm) and avoid donor-site morbidity associated with autograft. Synthetic nerve conduits are hollow biocompatible tubular implants intended to guide regenerating axons across short gaps and may be resorbable or nonresorbable. Comparative evidence is limited and heterogeneous; meta-analyses report mixed findings, with some analyses showing better meaningful recovery for allograft and autograft versus synthetic conduits, and overall insufficient evidence to show improved net health outcomes for many conduit indications.

Definitions

inv-20: Processed nerve allograft — definition and availability (lengths)

DefinitionHuman donor-derived nerve grafts processed to reduce immunogenicity and used as a scaffold to bridge peripheral nerve discontinuities

Availability — lengthsAvailable in multiple lengths and diameters to address cases where injury site is extensive

Guidance referenceReferenced by NICE IPG597 for processed nerve allografts

inv-21: Synthetic nerve conduit — definition (hollow tubular implants, resorbable/non-resorbable)

DefinitionHollow tubular biocompatible implants designed to guide regenerating nerve fibers across small nerve gaps

Material/behaviorAvailable in various biocompatible materials and may be resorbable (degrade over time)

Revision History

2025-08-01policy_effectiveLatest

New medical policy describing medically necessary and investigational indications for processed nerve allografts and synthetic nerve conduits became effective.